Allele Biotechnology and SCM Lifescience Sign a Joint Research and Development Agreement to Develop iPSC-based Diabetes Treatment

San Diego-based Allele Biotechnology and Pharmaceuticals, Inc.,officially announced a joint research and development agreement withSouth Korea’s SCM Lifescience Co., Ltd., for the development of diabetestherapies using pancreatic beta cells derived from induced pluripotentstem cells (iPSCs).

Read more

Alum-GAD is safe for children with increased risk for type 1 diabetes, but does not prevent developing it

A study that was presented at the American Diabetes Association’s Scientific sessions on Monday showed that treatment with autoantigen specific therapies, such as Alum-GAD, is safe to give to children with an increased risk for developing type 1 diabetes, however, it does not prevent the development of the disease.

Read more